Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Systemic sclerosis in 2014

Advances in cohort enrichment shape future of trial design

Nature Reviews Rheumatology volume 11, pages 72–74 (2015)Cite this article

Subjects

The treatment and study of systemic sclerosis (SSc) is entering a new era with the reporting and preparation of several randomized controlled trials according to an improved understanding of SSc pathogenesis. Advances in trial designs reported in 2014 should now be built upon with further improvements to patient selection to enable targeting of therapies to specific subgroups of patients with SSc.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The ceiling effect of baseline mRSS.

References

  1. Cobo-Ibáñez, T. et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin. Arthritis Rheum. http://dx.doi.org/10.1016/j.semarthrit.2014.04.002.

  2. Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 6, 498–506 (2011).

    Article  Google Scholar 

  3. van Laar, J. M. et al. EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 25, 2490–2498 (2014).

    Article  Google Scholar 

  4. Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum. 66, 1625–1635 (2014).

    Article  Google Scholar 

  5. Elhai, M., Meune, C., Avouac, J., Kahan, A. & Allanore, Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 51, 1017–1026 (2012).

    Article  Google Scholar 

  6. Nikpour, M. & Baron, M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr. Opin. Rheumatol. 26, 131–137 (2014).

    Article  Google Scholar 

  7. Clements, P. J. et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 42, 1194–1203 (1999).

    Article  CAS  Google Scholar 

  8. Nagaraja, V., Denton, C. P. & Khanna, D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) http://dx.doi.org/10.1093/rheumatology/keu285.

  9. Maurer, B. et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-205226.

  10. Merkel, P. A. et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 64, 3420–3429 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology A, Medicine Faculty, Paris Descartes University, 27 Rue du Faubourg Saint Jacques, Cochin Hospital, Paris, 75014, France

    Yannick Allanore

  2. Division of Rheumatology, University Hospital Zurich, Gloriastrasse 25, Zürich, 8091, Switzerland

    Oliver Distler

Authors
  1. Yannick Allanore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Distler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yannick Allanore.

Ethics declarations

Competing interests

Y.A. declares that he has received honoraria or research grants from Actelion, Bayer, Inventiva, Medac, Pfizer, Roche/Genentech, Sanofi and Servier. O.D. declares that he has consulted for, or has received research funding from, 4D Science, Actelion, Active Biotec, Bayer-Schering, Biogen, Biovitrium, BMS, Boehringer Ingelheim Pharma, EpiPharm, Ergonex, GSK, Inventiva, Medac, Novartis, Pfizer, Roche/Genentech, Sanofi/Genzyme, Serodapharm, Sinoxa and United BioSource Corporation.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Allanore, Y., Distler, O. Advances in cohort enrichment shape future of trial design. Nat Rev Rheumatol 11, 72–74 (2015). https://doi.org/10.1038/nrrheum.2014.222

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2014.222

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing